Theodore Alan Huizenga Ultragenyx Pharmaceutical Inc. (RARE) insider trading activity

Theodore Alan Huizenga is SVP, Chief Accounting Officer of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 42,251 shares of RARE, which is worth approximately $2.44 Million. The most recent transaction as insider was on Sep 16, 2024, when has been sold 700 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 42.3K

2.14% 3M change

78.92% 12M change

Total Value Held $2.44 Million

Theodore Alan Huizenga Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 16 2024	BUY Grant, award, or other acquisition	-	700 Added 1.63%	42,251 Common Stock
Sep 03 2024	SELL Open market or private sale	$5,113 $56.19 p/Share	91 Reduced 0.22%	41,551 Common Stock
Apr 16 2024	SELL Payment of exercise price or tax liability	$592 $42.31 p/Share	14 Reduced 0.03%	41,366 Common Stock
Mar 01 2024	SELL Open market or private sale	$18,332 $53.76 p/Share	341 Reduced 0.82%	41,380 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$6,496 $53.69 p/Share	121 Reduced 0.29%	41,721 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	13,950 Added 25.0%	41,842 Common Stock
Jan 02 2024	BUY Exercise of conversion of derivative security	$63,000 $21.0 p/Share	3,000 Added 9.71%	27,892 Common Stock
Dec 20 2023	BUY Grant, award, or other acquisition	-	1,000 Added 3.9%	24,614 Common Stock
Sep 07 2023	SELL Open market or private sale	$85,806 $39.67 p/Share	2,163 Reduced 8.39%	23,614 Common Stock
Sep 07 2023	BUY Exercise of conversion of derivative security	$42,000 $21.0 p/Share	2,000 Added 7.2%	25,777 Common Stock
Sep 01 2023	SELL Open market or private sale	$36,510 $37.64 p/Share	970 Reduced 3.92%	23,777 Common Stock
May 09 2023	BUY Exercise of conversion of derivative security	$63,000 $21.0 p/Share	3,000 Added 8.89%	30,747 Common Stock
Apr 16 2023	SELL Sale (or disposition) back to the issuer	$6,914 $38.2 p/Share	181 Reduced 0.65%	27,520 Common Stock
Apr 16 2023	SELL Payment of exercise price or tax liability	$534 $38.2 p/Share	14 Reduced 0.05%	27,701 Common Stock
Mar 01 2023	SELL Open market or private sale	$4,565 $45.65 p/Share	100 Reduced 0.43%	23,048 Common Stock
Mar 01 2023	SELL Sale (or disposition) back to the issuer	$60,851 $45.65 p/Share	1,333 Reduced 5.78%	21,715 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	7,590 Added 24.69%	23,148 Common Stock
Feb 28 2023	SELL Open market or private sale	$27,732 $43.4 p/Share	639 Reduced 3.95%	15,558 Common Stock
Dec 21 2022	SELL Open market or private sale	$89,282 $43.96 p/Share	2,031 Reduced 11.14%	16,197 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	-	1,000 Added 5.24%	18,094 Common Stock
Apr 16 2022	SELL Open market or private sale	$11,161 $84.55 p/Share	132 Reduced 0.77%	16,914 Common Stock
Mar 01 2022	SELL Open market or private sale	$56,161 $66.62 p/Share	843 Reduced 5.99%	13,229 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	3,710 Added 17.87%	17,046 Common Stock
Oct 14 2021	SELL Open market or private sale	$11,360 $81.14 p/Share	140 Reduced 0.99%	14,072 Common Stock
Sep 13 2021	SELL Bona fide gift	-	819 Reduced 5.45%	14,212 Common Stock

TAH

Theodore Alan Huizenga

SVP, Chief Accounting Officer

Novato, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RARE shares.

Notify only if

Value

Insider Trading

Get notified when an Ultragenyx Pharmaceutical Inc. insider buys or sells RARE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Ultragenyx Pharmaceutical Inc.

Track Activities on RARE

Account